CarolynDoloresBrittenMD

Oncology • Charleston, SC

Gastrointestinal Cancer, Hematologic Oncology

Director, Division of Hematology/Oncology Associate Professor at Medical University of South Carolina

Join to view full profile

Dr. Britten is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Britten's full profile

Already have an account?

Office
171 Ashley Ave
Charleston, SC 29425
Phone+1 843-792-1414

Fax+1 843-792-1190

Education & Training

University of Toronto Faculty of MedicineClass of 1992

Certifications & Licensure

CA State Medical License 2001 - 2026
SC State Medical License 2012 - 2025
TX State Medical License 1997 - 2009
American Board of Internal Medicine Medical Oncology
Royal College of Physicians and Surgeons of CanadaInternal Medicine
Royal College of Physicians and Surgeons of CanadaMedical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression Start of enrollment: 2001 Aug 01
Completed
Phase 1, Phase 2
Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction Start of enrollment: 2002 May 01
Completed
Phase 1
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery Start of enrollment: 2003 Jun 01
Completed
Phase 2
LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Dec 01
Completed
Phase 1
CP-724,714 in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2003 Jan 01
Completed
Phase 1
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2005 Oct 01
Unknown status
Phase 1
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Start of enrollment: 2009 Nov 01
Completed
Phase 1
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
Completed
Phase 1
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors Start of enrollment: 2013 Aug 01
Terminated
Phase 1
Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer Start of enrollment: 2013 Mar 01
Completed
Phase 1
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2013 Sep 30
Completed
Phase 1
Docetaxel and Lycopene in Metastatic Prostate Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors Start of enrollment: 2014 Apr 01
Terminated
Phase 1, Phase 2
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Start of enrollment: 2015 Sep 01
Completed
Phase 1
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma Start of enrollment: 2019 Sep 30
Withdrawn
Phase 2
AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy Start of enrollment: 2017 Jun 06
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

234 citations
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients w...
Philippe L. Bedard, Josep Tabernero, Filip Janku, Zev A. Wainberg, Luis Paz-Ares
Clinical Cancer Research. 2015-02-15
110 citations
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.
Carolyn D. Britten, Elizabeth Garrett-Mayer, Steven H. Chin, Keisuke Shirai, Besim Ogretmen
Clinical Cancer Research. 2017-08-15
78 citations
A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.
Carolyn D. Britten, Eric K. Rowinsky, Sharyn D. Baker, Geoffrey R. Weiss, Lon Smith
Clinical Cancer Research. 2000-01-01